Devonian Health Group Inc. (TSXV: GSD)

Market Cap	19.27M
Revenue (ttm)	22.39M
Net Income (ttm)	-864.74K
Shares Out	148.22M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,200
Average Volume	5,895
Open	0.130
Previous Close	0.160
Day's Range	0.130 - 0.130
52-Week Range	0.075 - 0.350
Beta	1.42
RSI	33.41
Earnings Date	Mar 27, 2025

About Devonian Health Group

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Luc Gregoire
• Employees: 8
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: GSD

Financial Performance

In 2024, Devonian Health Group's revenue was 17.82 million, an increase of 659.60% compared to the previous year's 2.35 million. Losses were -1.22 million, -73.38% less than in 2023.